3D Biotek
Develops 3D porous scaffolds and cell culture devices using precision micro-fabrication technology for stem cell research, tissue engineering, and drug discovery applications.
- CEO / Founder
- Wing Lau
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $225K
- Latest Round
- Grant
- Key Investors
- National Science Foundation
Technology & Products
Key Products
3D Insert PS scaffolds; 3D Insert PCL scaffolds; 3D Cell Expansion System; 3D Perfusion Bioreactor; Custom biomedical device fabrication
Technological Advantage
Proprietary scaffold fabrication process creates consistent 3D environments that better mimic in vivo conditions than 2D alternatives; technology enables integration with fluorescent/luminescent plates for direct assay compatibility.
Differentiation
Value Proposition
Provides physiologically relevant 3D cell culture environments that mimic in vivo conditions, enabling more accurate drug screening and stem cell research compared to traditional 2D methods.
How They Differentiate
Specializes exclusively in 3D scaffold technology rather than broader laboratory supplies; offers custom fabrication services for biomedical devices; proprietary integration with fluorescent/luminescent plates for direct assay compatibility.
Market & Competition
Target Customers
Academic researchers, pharmaceutical companies, biotechnology firms, cosmetics industry
Industry Verticals
Biotechnology; Pharmaceutical; Medical Research; Regenerative Medicine
Competitors
Thermo Fisher Scientific; Corning Incorporated; Merck KGaA; Lonza Group; Sartorius AG; InSphero AG; REPROCELL Inc.; Synthecon Inc.; Nanofiber Solutions; 3D Biomatrix (BICO Group); MIMETAS BV
Growth & Milestones
Growth Metrics
Revenue reported under $5 million; approximately 4-5 employees
Major Milestones
Founded in April 2007; Received '2009 Incubator Company to Watch' award; Granted Chinese utility model patent in 2009; FDA registered and ISO-13485-2016 certified
Notable Customers
KIYATEC